Explore more about: COVID-19

NIH, working in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), today announced a third round of contract awards for scale-up and manufacturing of new COVID-19 testing technologies.

Researchers have created a new PET imaging agent that detects signs of inflammation. Such a tracer could aid diagnosis and study of diseases ranging from cardiovascular disease to cancer to COVID-19.

NIH has awarded seven contracts to companies and academic institutions to develop digital health solutions that help address the COVID-19 pandemic.

NIH announced $129.3 million in scale-up and manufacturing support for a new set of COVID-19 testing technologies as part of RADx. These tests add to initial awards made to seven companies on July 31, 2020.

A new article looks at the use of virtual imaging trials in effective assessment and optimization of CT and radiography acquisitions and analysis tools to help manage the coronavirus disease (COVID-19) pandemic.

The National Institutes of Health has launched an ambitious effort to use artificial intelligence, computation, and medical imaging to enable early disease detection, inform successful treatment strategies, and predict individual disease outcomes of COVID-19.

NIH is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus). NIH’s RADx initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests.

El cuerpo humano contiene asombrosamente 60,000 millas de vasos sanguíneos, y todos esos tubos contienen detalles muy útiles acerca de cómo está funcionando el cuerpo. Para ciertos estados de enfermedad, tales como tumores cerebrales, el tamaño, la forma, y el número de vasos pueden revelar información crítica acerca del progreso o regresión de un tumor.